Healthcare

The federal development board for Southern Ontario has injected $5m to accelerate the growth potential of TIAP's early-stage health sciences portfolio.

Five years after being co-founded by UCL researchers, Ori Biotech has brought its overall funding to $41m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Oxford Nanopore has continued its funding streak with another $108m, bringing this year's haul to more than $208m and its overall total to around $800m.

MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.

Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.